Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.45
EPS est.
$-0.71
EPS surprise
+36.89%
1-day move
+0.01%
Guardant Health reported a narrower loss per share than analysts expected, which contributed to a slight increase in the stock price. However, there was no revenue reported, leaving investors with limited insights into the company's financial health. The lack of guidance and management commentary may lead to uncertainty among investors going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | $-0.47 | +36.89% |
| Revenue | — | $279M | — |
No transcript is on record, and the analysis is based on numerical results only.
Guardant Health, Inc. is a healthcare company focused on precision oncology, providing advanced genomic testing services for cancer detection and treatment. With a market cap of $12 billion, it operates in a growing sector that leverages technology to improve patient outcomes and streamline cancer care.
Last quarter
In the last quarter, Guardant Health reported an EPS of $-0.50, which was better than analysts' expectations of $-0.81, resulting in a positive surprise. However, revenue details were not disclosed, and the stock reacted negatively the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.61%
Avg 1-day reaction
+1.57%
Analysts expect Guardant Health to report a loss of $-0.47 per share on revenues of $279 million. The company has consistently surprised on the upside in previous quarters, which could lead to a positive market reaction.
Bull case
If Guardant Health beats EPS expectations again, it could signal strong operational efficiency and increased demand for its testing services, potentially driving the stock higher.
Bear case
A miss on EPS or revenue could raise concerns about the company's growth trajectory and market competitiveness, leading to a negative reaction from investors.
Key metrics to watch
EPS
$-0.47Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$279MRevenue figures are crucial for assessing the company's growth and market demand for its services.
The print will turn on these.
Q1
Will Guardant Health's EPS come in better than the consensus estimate of $-0.47?
A better-than-expected EPS could reinforce investor confidence and lead to a positive stock reaction.
Q2
What are the revenue figures compared to the consensus estimate of $279 million?
Revenue performance is critical for assessing growth and market demand, and any significant deviation could impact stock performance.
—
Est. EPS
$0.97
Est. Rev
$754M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate Guardant Health's ability to outperform due to its consistent track record of positive EPS surprises, indicating stronger operational resilience than analysts expect.
Supporting evidence
The company has beaten EPS estimates in every quarter for the last two years, showcasing operational strength.
Options are pricing a 14.1% move, which is significantly higher than the historical average of 4.3%, indicating potential overreaction to expected volatility.
Key risk
If the EPS comes in better than $-0.29, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether the company's recent positive surprises can continue amidst growing market competition.
Bull confirmed if
An EPS of better than $-0.29 would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS worse than $-0.82 would confirm the bear case and raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±14.1%
Historical Avg
±3.8%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±16.5% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
61.4%
Smart-money positioning from the most recent 13F filings.
Institutional
100.95%
of float
Insider
3.98%
of float
Holders
801
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
7,622,935 sh · $1.3B
5.68%
-34.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Guardant Health beats expectations, history suggests the stock could rise by about 2.1%, confirming the company's operational strength.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
If the company misses expectations, history suggests a potential decline of around 4.3%, reflecting investor disappointment.
The lines on the call that would change the story.
Price (T.Rowe) Associates Inc
6,514,952 sh · $1.1B
4.85%
-7.2%
Vanguard Capital Management LLC
5,755,857 sh · $968.9M
4.29%
2.3%
FMR, LLC
5,488,272 sh · $923.8M
4.09%
33.3%
Vanguard Portfolio Management LLC
5,445,785 sh · $916.7M
4.06%
-6.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.